ClinicalTrials.gg
Active, not recruitingNCT05935176Updated Mar 4, 2026

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

A Phase 4 interventional study of MCV4 and MCV4 in Epidemic Meningitis, sponsored by CanSino Biologics Inc.. Active, not recruiting at 1 site in China. Open to participants aged 6 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by CanSino Biologics Inc. · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
6 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Meningitis, Meningococcal with a site in China — 5 open to participants now, 8 under way, 5 of them phase 3. Meningitis, Meningococcal · China.

Enrollment
13th of 19
660 · median 840
Started
2023
with 1 other
Phase 4
2 of 19
none open now
Registered
9th of 19
by date
Lead sponsor
6 of 19
CanSino Biologics Inc.

Among the 19 studies in Meningitis, Meningococcal with a site in China, this one is the 13th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 4, and was the 9th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

5 of the 19 studies in Meningitis, Meningococcal with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 6 Months to 23 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Meningitis, Meningococcal with a site in China, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the immunogenicity and immunopersistence of the ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector).The protocol consists of two parts: Part 1 enrolled 660 eligible participants aged 6 to 23 months, which has now been completed. Part 2 : Open Clinical Researchplans to enroll approximately 100 eligible participants from Part 1 who have completed immunopreservance blood sampling. Participants will receive a single booster dose of the ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) at age 3 years (but not yet 4 years).

Read the detailed description

Meningococci are divided into 12 serogroups, and 95% of meningococcal cases are caused by serogroups A, B, C, X, W, and Y. Meningococcal epidemic flora can change, and the reasons are related to various factors such as meningococcal strain variation, human mobility transmission, and vaccination against different serogroups of meningococci, etc. The emergence of new serogroups of meningococci can cause the original vaccine to lose its immune protective efficacy and require a new vaccine immunization prevention strategy. the ACYW135 group meningococcal polysaccharide conjugate vaccine was approved in 2016 for a whole population The vaccine has been approved by the State Drug Administration for the prevention of epidemic meningoencephalitis caused by meningococci of groups A, C, W135 and Y in children from 3 months to 3 years of age (47 months of age).

03

Conditions studied

  • Epidemic Meningitis

Keywords

  • ACYW135
  • CRM197
  • Immunogenicity
  • Persistence
  • 6~23 months of age
  • 3 years old
04

Who can participate

Ages eligible
6 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part Ⅰ

Inclusion Criteria:

  • Children aged 6 to 23 months at the time of screening
  • Volunteers who have not received any vaccine containing a epidemic encephalitis component or who have received only the group A polysaccharide flu vaccine and have been vaccinated more than 6 months since their last vaccination. 6 months or more between the last vaccination and the last vaccination
  • The legal guardian or delegate has given , voluntarily signed the informed consent form, and is able to comply with the requirements of the clinical study protocol

Exclusion Criteria:

  • Fever before inoculation, axillary temperature >37.0℃
  • History of epilepsy, convulsions or seizures or history of psychiatric disorders or family history
  • During an acute illness episode; with a serious chronic illness or a condition that is in a progressive stage that cannot be smoothly controlled (or an acute episode)
  • Known allergy to a component of the vaccine, especially to diphtheria toxoid
  • received within 14 days or other vaccine received within 7 days prior to enrollment
  • Other circumstances that, in the judgment of the investigator, make participation in this clinical study inappropriate
  • Those who had a severe allergic reaction after the previous dose of vaccine
  • Those with serious adverse reactions causally related to the previous dose of vaccination
  • Newly identified or newly occurred cases after the first vaccination that do not meet the inclusion criteria for the first dose or meet the exclusion criteria for the first dose will be determined by the investigator whether to continue to participate in the study

Part Ⅱ

Inclusion Criteria:

  • The first phase of the study has been completed, involving the (0, 3) month vaccination schedule group for subjects aged 6 to 11 months. All subjects received two doses as required, and blood samples were collected 30 days after the primary vaccination series.
  • Children aged 3 years at the time of screening
  • The trial participant is able and willing to comply with the requirements of the clinical trial protocol and can complete the 1-month study follow-up.
  • The trial participants did not receive any meningococcal vaccine booster doses at age 3 years
  • The legal guardian or authorized representative voluntarily signs the informed consent form with full knowledge and understanding, and is able to comply with the requirements of the clinical research protocol.

Exclusion Criteria:

  • Fever prior to vaccination, with axillary temperature >37.0°C
  • History of epilepsy, convulsions, or seizures; psychiatric history or family history of psychiatric disorders
  • During acute phase of illness; severe chronic disease or progressive condition not well controlled (or in acute phase)
  • Known allergy to any vaccine component, particularly diphtheria toxoid
  • Receipt of live attenuated vaccines within 14 days or other vaccines within 7 days prior to enrollment
  • Other conditions deemed ineligible for this clinical study by the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
660 participants (actual)

Study arms

  • Experimental
    Part Ⅰ: Vaccine Group A

    2 dose of ACYW135 group meningococcal polysaccharide conjugate vaccine(MCV4) (0.5ml)

    Biological: MCV4

  • Experimental
    PartⅠ: Vaccine Group B

    2 dose of MCV4 (0.5ml)

    Biological: MCV4

  • Experimental
    Part Ⅱ: Vaccine Group C

    1 dose of MCV4 (0.5ml) at 3 years old from group B in Part I

    Biological: MCV4

Interventions

  • BiologicalMCV4

    2 dose of MCV4 on Day 0 and Month 1

  • BiologicalMCV4

    2 dose of MCV4 on Day 0 and Month 3

  • BiologicalMCV4

    1 booster dose of MCV4 at 3 years old

06

What researchers measure

Primary outcomes

  1. Antibody positivity for A, C, Y and W135 in all subjects 6 months after 2 dose exemption

    Time frame: 6 months after 2 dose exemption

  2. Seroconversion rates for serotypes A, C, Y, and W135

    Time frame: 30 days post-booster vaccination

  3. Geometric mean titers (GMTs) for serotypes A, C, Y, and W135

    Time frame: 30 days post-booster vaccination

  4. Increased incidence of adverse reactions

    Time frame: Within 7 days after post-booster vaccination

Secondary outcomes

  1. Antibody positivity for A, C, Y and W135 in all subjects 9 months after 2 dose exemption

    Time frame: 9 months after 2 dose exemption

  2. A, C, Y and W135 antibody positive conversion rate, positivity rate, GMT, GMI, ≥1:128 ratio in all subjects at 30 days after dose 2 exemption

    Time frame: 30 days after dose 2 exemption

  3. A, C, Y and W135 antibody GMT, GMI, ≥1:128 ratio in all subjects at 6 and 9 months after 2 dose exemption

    Time frame: 6 and 9 months after 2 dose exemption

  4. A, C, Y and W135 antibody GMT, positivity rate, GMI 30 days, 60 days after the first dose, and before the second dose in some subjects of the (0, 3) month immunization program

    Time frame: 30 days , 60 days after the first dose, and before the second dose

  5. Increased incidence of adverse events

    Time frame: Within 7 days after post-booster vaccination

  6. Increased Incidence of adverse reactions/events

    Time frame: Within 30 days after post-booster vaccination

  7. A, C, Y, and W135 Antibody Positivity Rates and GMI and ≥1:128 Proportions

    Time frame: Within 30 days after post-booster vaccination

07

Study locations

1 site
  • Wuzhi County Center for Disease Control and Prevention
    Jiaozuo, Henan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for May 2026, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 7, 2023
StartActual
Sep 20, 2023
Primary completionEst.
May 15, 2026
CompletionEst.
Jul 15, 2026
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05935176
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Sep 20, 2023
Primary completion
May 15, 2026 (estimated)
Completion
Jul 15, 2026 (estimated)
Last update
Mar 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion